STOCK TITAN

Theravance Bioph - TBPH STOCK NEWS

Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.

Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.

This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.

Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.

Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.

Rhea-AI Summary

Theravance Biopharma has appointed Jim Kelly, Managing Director at Weiss Asset Management and the Company's second largest shareholder, to its Board of Directors. This appointment is part of an ongoing board refreshment strategy, which has seen four new directors join since 2018. CEO Rick E Winningham emphasized Kelly's investment experience and understanding of the healthcare industry as valuable assets for the board. Kelly expressed commitment to leveraging his experience for the Company's success and shareholder returns. Weiss Asset Management manages approximately $3 billion in assets and has been a significant shareholder since 2021. Theravance focuses on developing impactful medicines, including the FDA-approved YUPELRI for COPD treatment and the investigational drug Ampreloxetine for neurogenic orthostatic hypotension.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
management
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:45 pm ET. The event will be accessible via webcast on Theravance.com in the Investors section.

Theravance Biopharma focuses on delivering innovative medicines, notably the FDA-approved YUPELRI (revefenacin) inhalation solution for chronic obstructive pulmonary disease (COPD). Additionally, the company is developing Ampreloxetine, a potential first-in-class norepinephrine reuptake inhibitor aimed at treating neurogenic orthostatic hypotension.

For further details about the conference and the company’s developments, visit www.theravance.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, at 10:30 am ET. The event will include a Respiratory/Infections Corporate Panel Discussion.

The conference will be accessible via webcast on Theravance.com, where a replay will be available for 30 days. Theravance Biopharma is known for its FDA-approved YUPELRI® inhalation solution for COPD and is developing Ampreloxetine, targeting neurogenic orthostatic hypotension. The firm's commitment is towards improving patient lives and increasing shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
Rhea-AI Summary

Theravance Biopharma (TBPH) has announced significant strategic moves, including increasing its capital return program from $250 million to $325 million. As of February 27, 2023, approximately $170 million remains in this program. The company reported $19.5 million in YUPELRI® sales for Q4 2022, a 27% year-over-year increase, marking its strongest quarter. Additionally, Theravance will discontinue research investments and reduce headcount by 17% to focus resources on the ampreloxetine Phase 3 study. The company reaffirmed its guidance for non-GAAP profitability in the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary

Irenic Capital Management, a major shareholder of Theravance Biopharma (NASDAQ: TBPH), criticized the company's leadership and called for strategic changes. Since its separation in 2014, Theravance's total shareholder return has plummeted by -50%, reflecting a significant discount in its market value. Irenic proposed actions such as returning $300 million in excess cash to shareholders, reducing operational costs, and improving governance by appointing a shareholder representative. They estimate that adopting these measures could unlock nearly $21 per share in value, substantially higher than its current trading price of $9.87.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
none
-
Rhea-AI Summary

Theravance Biopharma (TBPH) will announce its fourth quarter and full-year 2022 financial results on February 27, 2023, after market close. A conference call and webcast are scheduled for 5:00 PM ET on the same day, allowing investors to gain insights into the company's performance. Interested parties can participate by pre-registering online. The company is known for its FDA-approved drug, YUPELRI, aimed at treating COPD and continues to focus on developing new therapies for unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences earnings
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 8:00 am ET. The event can be accessed via a webcast on Theravance.com in the Investors section. A replay will be available for 30 days post-event. Theravance Biopharma is committed to delivering Medicines that Make a Difference and is known for its FDA-approved YUPELRI® inhalation solution for COPD. The company focuses on addressing significant unmet patient needs through its innovative pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (TBPH) announced significant 2022 achievements and 2023 objectives. Key highlights include strategic advances in YUPELRI sales growth, with all-time high net sales reported in Q2 and Q3. The company initiated the Phase 3 CYPRESS study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) planned for Q1 2023, alongside a $250 million capital return program. With FDA discussions and a $1.1 billion royalty sale, Theravance aims for Non-GAAP profitability by 2H 2023, reinforcing its commitment to delivering impactful medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
none
-
Rhea-AI Summary

On November 22, 2022, Theravance Biopharma (NASDAQ: TBPH) announced the final results of its Dutch auction tender offer, which aimed to purchase up to $95 million of its ordinary shares. The offer expired on November 17, 2022, with a total of 115,967 shares tendered and accepted at $10.50 each, totaling approximately $1.2 million. This amount represents about 0.2% of the shares outstanding. The company plans to use the unused funds for an open market share repurchase program expected to commence after the tender offer's completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
none
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) announced the preliminary results of its Dutch auction tender offer, intending to purchase up to $95 million of ordinary shares. The offer expired on November 17, 2022, with 115,967 Shares tendered. The company plans to purchase these shares at $10.50 each, totaling approximately $1.2 million. This represents about 0.2% of the total shares outstanding. Additionally, the unused portion of the offer will fund an open market share repurchase plan expected to begin after the tender offer concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
none
Theravance Bioph

Nasdaq:TBPH

TBPH Rankings

TBPH Stock Data

471.95M
47.61M
6.22%
93.64%
7.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
GEORGE TOWN, GRAND CAYMAN